Compugen Ltd.

NASDAQ:CGEN

Biotechnology

Healthcare
$2.02 +0.50%

+$0.01 today

Market cap
$191.34M
Beta
2.74
P/E (TTM)
5.4
EPS (TTM)
$0.37
52W Low $1.30High $3.24

Volume 0.20M

Average 0.48M

CGEN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Compugen Ltd.NASDAQ: CGEN

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$7.66M, compared with -$7.15M a year earlier. Trailing-twelve-month EBITDA was $34.88M.

Context

  • EBITDA amounted to 49.3% of revenue in FY2025, up 16.3 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of -$23.24M (-164.8%) for the fiscal year ending Dec 2026, a slowdown from the +490.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.66M-113.5% QoQ
Last fiscal yearDec 2025
$35.87M+490.4% YoY
LTMMar 2026
$34.88M+463.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.2%-1.6%+5.6 pp
1 year+490.4%-164.8%-655.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
35.87M USD
Year-over-year change
+490.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CGEN compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +463.6% is the highest of 9, against a peer median of -10.4%.
  • EBITDA amounts to 48.0% of revenue for CGEN, versus a peer median of 1566.1%.
CGEN Competitors
EBITDA for CGEN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGENCompugen Ltd.LTM Mar 2026$34.88M USD+463.6%—48.0%
NVCTNuvectis Pharma, Inc.LTM Mar 2026-$28.06M USD-39.2%——
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026-$33.38M USD+31.6%—1053.3%
IPHAInnate Pharma S.A.FY2025-€43.65M EUR+7.0%—1566.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026-$43.73M USD+9.5%—8329.5%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$61.36M USD-27.4%—3439.7%
MOLNMolecular Partners AGLTM Mar 2026-CHF 63.08M CHF-8.3%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026-$84.28M USD-67.4%——
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026-$145.4M USD-12.5%—828.2%
Peer median (excluding CGEN) —-10.4%—1566.1%

Competitors are the stored peer set for CGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6M7.5M33.46M27.86M72.76M
Cost of Revenue680K975K2M7.93M9.25M
Gross Profit5.32M6.53M31.46M19.93M63.51M
Gross Margin88.7%87.0%94.0%71.5%87.3%
Research & Development28.69M30.65M34.47M24.81M22.76M
Selling, General & Admin11.7M11.25M9.98M10.02M9.43M
Operating Expenses40.39M41.9M44.45M34.83M32.19M
Depreciation & Amortization461K482K476K486K475K
EBITDA(33.72M)(33.13M)(9.28M)(9.19M)35.87M
EBITDA Margin-562.0%-441.7%-27.7%-33.0%49.3%
Operating Income(35.07M)(35.37M)(12.99M)(14.89M)31.33M
Operating Margin-584.6%-471.7%-38.8%-53.4%43.1%
Interest Income894K1.44M3.24M5.24M4.41M
Interest Expense25K27K31K34K0
Other Income / Expenses871K1.74M3.21M5.18M4.07M
Income Before Tax(34.2M)(33.64M)(9.78M)(9.71M)35.4M
Pre-Tax Margin-570.0%-448.5%-29.2%-34.8%48.6%
Income Tax Expense058K8.97M4.52M54K
Net Income(34.2M)(33.69M)(18.75M)(14.23M)35.34M
Net Margin-570.0%-449.3%-56.1%-51.1%48.6%
EPS (Basic)(0.41)(0.39)(0.21)(0.16)0.38
EPS (Diluted)(0.41)(0.39)(0.21)(0.16)0.38
Weighted Avg Shares84.2M86.56M87.63M89.53M93.43M
Weighted Avg Shares (Diluted)84.2M86.56M87.63M89.53M93.82M

Compugen Ltd.

NASDAQ:CGEN

Intrinsic Alpha fair value

Locked

Current Price

$2.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.